CGIX acquires (private) NovellusDx in all-stock deal for 49% of combined company: https://globenewswire.com/news-release/2018/09/18/1572410/0/en/Cancer-Genetics-and-NovellusDx-Sign-Definitive-Agreement-to-Merge.html This deal is on the cusp of being characterized as a reverse merger.